RATIONALE: We demonstrated CD49d expressing neutrophils (CD49d+ PMN) accumulate in human nasal lavage with cold symptoms or following allergen challenge. Both human and mouse CD49d+ PMN express cysteinyl leukotriene receptor 1 (CysLTR1). In mice, CysLTR1 blockade increased CD49d+ PMN apoptosis and prevented post-viral atopic disease. This study evaluated whether CysLTR1 blockade prevents human nasal lavage CD49d+ PMN accumulation post allergen challenge. METHODS: Subjects (n525; 13 female; 32(25-58) years old, median(-range)) were randomized to receive placebo or 10mg montelukast daily for 1 week. After skin testing, a nasal lavage was performed, then an allergen challenge, with a repeat lavage 6 hours later. Subjects were then crossedover to the other treatment for a week, and repeat challenge/lavages performed. Number of CD49d+ PMN in nasal lavage determined by flow cytometry. RESULTS: CD49d+ PMN counts trended to increase with allergen challenge on placebo (9306230-1945 to 12556552-5084; p50.19; n513; median6IQR number of CD49d+ PMN in nasal lavage pre to post challenge), while there was no increase with montelukast (4436216-1246 to 7926156-1559; p50.72; n514). Interestingly, the montelukast effect was greatest in subjects who were given the drug during the first week (4946328-746 to 4446116-1131; p50.55; n58) compared to the second week (2496123-11030 to 17066396-2970; p50.84, n56). CONCLUSIONS: There was a trend for increased CD49d+ PMN in the nasal lavage of allergic subjects treated with a placebo. CysLTR1 blockade with montelukast prevented a significant increase in nasal lavage CD49d+ PMN with allergen challenge, although an allergen challenge one week earlier seemed to blunt this prevention.
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Butyrate and propionate regulated proliferation and activation of human group-2 innate lymphoid cells (ILC2s) Keisuke Orimo, M.D. 3 Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan. RATIONALE: Commensal intestinal microbiota are thought to play fundamental roles in the induction, training and regulation of the human immune system, at least in part through innumerable microbial products such as short-chain fatty acids (SCFAs). We hypothesized that SCFAs such as butyrate, propionate and acetate directly affect group-2 innate lymphoid cell (ILC2) functions and regulate allergic inflammation. To test this hypothesis, we determined the effects of SCFAs on human ILC2s in vitro. METHODS: Human ILC2s were sorted from peripheral blood lymphocytes (PBMC) of healthy donors and expanded in the presence of feeder cells and recombinant IL-2 for 3-4 weeks. After confirming their purity, the ILC2s were cultured with IL-2 and IL-33 in the presence and absence of such SCFAs as butyrate, propionate and acetate. Then the cells' viability, proliferation and cytokine/chemokine production were determined. RESULTS: We found that butyrate and propionate suppressed the ILC2s' production of such type 2 cytokines/chemokine as IL-5, IL-9, IL-13 and IL-8 . Butyrate and propionate also induced apoptosis and suppressed proliferation of the cells through downregulation of IL-2Ra. Conversely, acetate showed none of those effects on the cells. CONCLUSIONS: Butyrate and propionate, but not acetate, produced by the intestinal microbiota may play important roles in regulating the proliferation activation and cytokine/chemokine production profiles of ILC2s, thereby leading to regulation of allergic inflammatory diseases.
The Effect of Hydroxytolans on Macrophages
Boren Lin, PhD, Olivia Miller, Nur-E. Alom, Fan Wu, Wei Li, PhD, and Jianyang Du, PhD; The University of Toledo, TOLEDO, OH. RATIONALE: A group of hydroxytolans were previously found capable of suppressing tumor cell growth. The most current study further evaluated their regulatory effects on inflammation, a common factor in many diseases including cancer, arthritis and cardiovascular disorders. METHODS: The study focused on macrophages, an immune cell type responsible for chronic inflammation. Cell viability assays were conducted to assess the effect of hydroxytolans, at various concentrations for 24h, on murine macrophage cell line RAW 264.7, compared to murine fibroblast L292 cells. Quantitative RT PCR analysis was conducted to detect activation of inflammatory genes (TNFa, IL-1, IL-6 and iNOS) in response to LPS stimulation (2.5 mg/mL, 2h) after hydroxytolan treatment (50 mg/ mL, 0.5h). NF-kB activation is one of the underlying mechanisms for LPSinduced inflammation, and its regulation was investigated by using a luciferase assay on RAW 264.7 cells following hydroxytolan treatment (50 mg/mL, 0.5h) and LPS stimulation (2.5 mg/mL, 6h). In addition, phosphorylation of JNK, one of the key molecules driving the signal pathway for induction of pro-inflammatory cytokine was assessed by Western blot analysis after hydroxytolan treatment (50 mg/mL, 0.5h) and LPS stimulation (2.5 mg/mL, 0.5h). RESULTS: RAW 264.7 macrophages were more susceptible to 4,4'-dihydroxytolan in terms of cell viability, compared to non-macrophage L292 cells. Pre-treating RAW 264.7 with both 4,4'-dihydroxytolan and 3,4',5-trihydroxytolan attenuated LPS-induced expression of cytokines and iNOS, NF-kB activation, and JNK phosphorylation. CONCLUSIONS: Together our data implicated that these drug candidates exhibited an inhibitory effect on macrophages, suggesting a therapeutic potential of hydroxytolans for the treatment of macrophagemedicated inflammatory diseases.
